Healthcare / BiotechnologyNasdaqCM
$4.11
+0.00 (+0.00%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 25% · confianza 25%
FCF escenarios
weak_data · normalized FCF n/d · quality 50.0/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
1/100
F
Piotroski
2/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
20/100
SEC 0%
Sin guardar todavía.
Market Cap
$96M
P/E
N/A
•EV/EBITDA
N/A
•ROE
-49.3%
↓Gross Margin
N/A
•Debt/Equity
N/A
•Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2021–2025 · 4 años de histórico normalizado
Revenue CAGR
—
FCF CAGR
—
FCF margin
—
FCF / Net income
—
Latest source
Provider fallback
Margin decomposition
Último año: revenue $7.9M · net income $-21.2M · FCF —
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|---|
| Income Statement | ||||||
| Revenue | $7.9M | $7.9M | $3.6M | $6.0M | $0.00 | — |
| Net Income | $-21.2M | $-21.2M | $-14.9M | $-8.0M | $-12.2M | $-4.9M |
| EPS | -1.27 | -1.27 | -0.98 | -0.79 | -4.73 | -1.89 |
| Operating Margin | -283.9% | -283.9% | -485.4% | -131.7% | — | — |
| Net Margin | -267.1% | -267.1% | -418.7% | -133.1% | — | — |
| Returns | ||||||
| ROE | -49.3% | -49.3% | -37.6% | -22.4% | 145.9% | -134.3% |
| Growth & Yield | ||||||
| Revenue Growth | 123.6% | 123.6% | -40.8% | — | — | — |
| EPS Growth | -29.6% | -29.6% | -24.1% | 83.3% | -150.3% | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Unavailable: positive start/end prices are required.